×
About 44,328 results

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
https://clinicaltrials.gov/ct2/show/NCT03412565

Jun 21st, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...

What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day M...
https://doi.org/10.1007/s11523-022-00897-8 10.1016/S0140-6736(21)00135-5 10.1056/NEJMra1011442 10.1016/S1470-2045(14)70442-5 10.3322/caac.21660 10.1001/jama.2022.0003 10.1016/j.mayocp.2012.06.014 10.1177/095952874402700129 10.1056/NEJMoa2024850 10.1097/PPO.0000000000000523 10.1097/HS9.0000000000000163 10.1002/ajh.25791 10.3390/cancers13061285 10.3390/cancers13194787 10.1038/s41408-021-00550-z 10.1007/s11523-020-00758-2 10.1177/2040620721989585 10.3390/cancers12123576 10.1016/j.ejca.2016.10.018 10.1016/j.annonc.2020.11.014 10.1016/S0140-6736(19)31240-1 10.18632/oncotarget.27973 10.2217/14796694.2.5.577 10.1016/s0190-9622(96)90122-x 10.1038/sj.leu.2403852 10.1038/nrc1323 10.1016/s0022-3476(64)80626-0 10.1177/2040620711413165 10.1016/s0029-7844(01)01662-3 10.1002/bdrc.21096 10.1002/cpt196563292 10.1002/cpt196563298 10.1002/cpt196563303 10.1517/14656566.1.4.849 10.1097/00124743-200002000-00003 10.1046/j.1440-0960.2002.00608.x 10.1093/toxsci/kfr088 10.1016/s0149-2918(03)80085-1 10.1517/13543784.7.12.2043 10.1073/pnas.91.9.4082 10.1038/nm0195-27 10.1111/j.1365-2141.1994.tb08304.x 10.3109/10428199509054750 10.1177/1078155220975825 10.1177/2042098612452291 10.1053/j.seminoncol.2016.10.008 10.1111/imr.12233 10.1053/ctrv.2000.0188 10.1016/j.ejca.2006.02.017 10.3389/fonc.2020.625199 10.1182/blood-2004-07-2909 10.1007/s002770000236 10.3343/alm.2015.35.6.563 10.1038/sj.bmt.1704555 10.1182/blood-2002-08-2441 10.1006/exer.1997.0292 10.1186/1471-2121-7-17 10.1111/j.1476-5381.2009.00446.x 10.1200/JCO.2005.03.723 10.3390/jcm9061765 10.3390/ijms19072031 10.1038/sj.leu.2403285 10.1182/blood.v99.12.4525 10.3390/ijms17091506 10.1038/leu.2009.236 10.3389/fimmu.2021.632399 10.1084/jem.187.11.1885 10.1182/blood-2003-02-0361 10.1182/blood.v98.1.210 10.1023/a:1026548226770 10.1007/s12185-016-2073-4 10.1126/science.1177319 10.1182/blood-2011-05-356063 10.3389/fcell.2021.629326 10.1038/s41598-020-57512-x 10.1155/2017/9130608 10.3390/ph13050095 10.1016/j.biopha.2020.110114 10.1126/science.1249543 10.1097/PPO.0000000000000354 10.1038/nature14610 10.1038/s41589-020-0645-3 10.1182/blood-2007-10-078022 10.1111/ejh.13003 10.1038/sj.leu.2403728 10.1016/s0140-6736(83)90739-0 10.1182/blood.V67.5.1298.1298 10.1182/blood.V70.3.869.869 10.1056/NEJM199607113350204 10.1056/NEJMoa032290 10.1182/blood.V92.9.3131 10.1056/NEJM198405243102104 10.1200/JCO.1989.7.10.1514 10.1186/2162-3619-1-27 10.1056/NEJM199911183412102 10.1182/blood.v98.2.492 10.1023/a:1011132808904 10.1182/blood.v98.13.3846 10.1038/sj.thj.6200175 10.1182/blood-2002-09-2846 10.1016/S0953-6205(03)91244-1 10.1046/j.1365-2141.2003.04473.x 10.1200/JCO.2003.01.055 10.1111/j.1365-2141.2004.04879.x 10.4065/79.7.875 10.1038/sj.thj.6200401 10.1038/sj.leu.2403322 10.1038/sj.thj.6200326 10.1038/sj.thj.6200403 10.1038/sj.leu.2403890 10.1007/s00277-005-1007-7 10.1200/JCO.2005.14.381 10.1111/j.1365-2141.2005.05521.x 10.1158/1078-0432.CCR-05-0213 10.4065/81.7.889 10.3816/CLM.2006.n.028 10.1182/blood-2006-08-042275 10.1634/theoncologist.12-1-99 10.1111/j.1600-0609.2007.00908.x 10.1111/j.1600-0609.2007.00930.x 10.1111/j.1349-7006.2008.00792.x 10.1111/j.1365-2141.2008.07360.x 10.1038/leu.2008.99 10.1038/leu.2008.235 10.1111/j.1365-2141.2008.07076.x 10.1111/j.1600-0609.2008.01131.x 10.1007/s00277-009-0856-x 10.1038/leu.2010.58 10.1007/s00277-010-0943-z 10.1007/s00277-011-1276-2 10.1007/s00277-011-1217-0 10.1007/s00277-011-1320-2 10.1111/j.1600-0609.2011.01729.x 10.3324/haematol.2011.044271 10.1111/j.1600-0609.2012.01775.x 10.1200/JCO.2011.37.4918 10.3109/10428194.2012.664844 10.1002/ajh.23822 10.1111/bjh.13435 10.1111/bjh.14263 10.1016/S2352-3026(16)30165-X 10.1002/cam4.970 10.1007/s00280-017-3310-0 10.1111/bjh.15645 10.1038/s41416-019-0581-8 10.1002/ajh.25633 10.1111/bjh.17504 10.1182/blood-2010-10-299487 10.1111/j.1365-2141.2005.05914.x 10.1182/blood.V96.9.2943 10.1111/j.1600-0609.2008.01121.x 10.5045/br.2020.S008 10.20471/acc.2018.57.03.18 10.1002/ajh.24181 10.1111/bjh.14481 10.1038/s41408-019-0219-3 10.1182/blood.v98.5.1614 10.1111/bjh.12325 10.1182/blood.V122.21.5377.5377 10.1182/blood.V124.21.3459.3459 10.1111/bjh.17248 10.1002/ajh.24954 10.1111/j.1365-2141.2007.06921.x 10.1159/000365534 10.2147/CMAR.S105163 10.1111/bjh.13296 10.1001/jamaoncol.2017.4519 10.1182/blood-2020-139092 10.1016/j.critrevonc.2017.02.007 10.1345/aph.1A155 10.1038/sj.leu.2405062 10.1111/j.1365-2141.2010.08416.x 10.1016/j.mayocp.2017.01.003 10.3904/kjim.2013.28.3.263 10.1200/JCO.2005.03.0221 10.1200/EDBK_238527 10.1038/leu.2015.80 10.1182/blood-2016-01-693580 10.1111/bjh.12946 10.1111/j.1365-2141.2008.06982.x 10.3324/haematol.2018.205476 10.1590/1413-812320182410.28522017 10.1007/s00277-016-2660-8 10.1182/blood-2011-11-374249 10.1097/SPC.0b013e328349dc17 10.1182/blood-2006-05-022962 10.1038/s41408-020-0273-x 10.1182/blood-2011-06-357038 10.1200/JCO.2009.25.6081 10.1080/10428194.2019.1683736 10.1182/blood-2011-03-341669 10.3389/fmed.2021.612696 10.1056/NEJMoa1402551 10.1182/blood-2014-12-613927 10.1182/blood-2015-11-679415 10.1080/14656566.2016.1236915 10.1016/j.hkjn.2013.09.001 10.3390/cancers13205036 10.1016/j.kint.2020.11.010 10.18632/oncotarget.26270 10.2215/CJN.06100616 10.1182/blood-2007-10-117457 10.1177/0091270007309563 10.1111/j.1600-0609.2004.00272.x 10.3324/haematol.10759 10.1016/j.bbmt.2010.02.020 10.1182/blood-2011-05-353995 10.1111/j.1365-2141.2011.08754.x 10.1038/leu.2012.182 10.3324/haematol.2015.133629 10.1182/blood-2019-128157 10.1182/blood-2011-11-395749 10.1007/s12185-008-0055-x 10.1056/NEJMoa1607751 10.3389/fmolb.2021.788440 10.1111/bjh.17805 10.1186/s40364-021-00344-2 10.1016/S0140-6736(21)00933-8 10.1016/j.annonc.2021.12.003 10.1016/S1470-2045(19)30788-0 10.1177/2040620720979813 10.1182/blood-2020-139332 10.1155/2012/621958 10.1158/1535-7163.MCT-18-1146 10.1158/1078-0432.CCR-17-0344 10.1038/s41408-021-00469-5 10.1182/bloodadvances.2020002524 10.1158/2643-3230.BCD-21-0073 10.1126/scitranslmed.abb6295 10.1001/jamanetworkopen.2021.16357 10.1001/jamanetworkopen.2021.3497
Targeted Oncology; Costa BA, Mouhieddine TH et. al.

Jul 1st, 2022 - Immunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind to cereblon, leading to the degradation of proteins involved in B-cell survival and proliferation. Thalidomide, a first-generation IMiD, has little to no myelosuppressive potential, negligible renal clearance, and long-proven anti-myeloma ac...

Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Syste...
https://doi.org/10.1007/s12325-022-02195-1 10.1053/j.seminoncol.2016.11.004 10.1186/s13045-019-0807-5 10.1634/theoncologist.2020-0141 10.3389/fonc.2019.01513 10.1002/cam4.3391 10.1038/bcj.2014.55 10.1016/j.bbmt.2014.12.013 10.1136/bmj.b2700 10.1371/journal.pmed.1000097 10.1136/bmj.i4919 10.1186/1471-2288-11-41 10.1037/1082-989X.11.2.193 10.1097/MD.0000000000015987 10.1038/leu.2017.211 10.1186/s40164-018-0110-0 10.1038/s41408-018-0106-3 10.1016/j.clml.2019.09.597 10.1038/s41375-019-0384-1 10.1007/s00277-019-03815-7 10.1016/S0140-6736(19)31240-1 10.4067/S0034-98872019001201561 10.1016/j.clml.2019.09.362 10.1182/blood.2019000241 10.1016/j.clml.2019.09.341 10.1007/s10147-019-01436-8 10.1159/000495338 10.1016/S2352-3026(20)30099-5 10.3747/co.27.5385 10.1182/blood.2020007522 10.1111/ejh.13349 10.1007/s12185-019-02764-1 10.1016/S2352-3026(20)30323-9 10.1182/blood.2020005288 10.1371/journal.pmed.1003454 10.1111/j.1365-2141.2008.06997.x 10.1200/JCO.2008.19.5370 10.1007/s00277-009-0726-6 10.1038/leu.2009.26 10.1111/j.1365-2141.2009.07981.x 10.1016/S0140-6736(10)61424-9 10.1182/blood-2010-02-271676 10.1177/147323001103900544 10.1182/blood-2011-05-355081 10.1182/blood-2012-02-408922 10.1200/JCO.2011.39.6820 10.1200/JCO.2011.39.5137 10.3324/haematol.2013.100396 10.1111/bjh.13004 10.1200/JCO.2013.54.8164 10.1111/bjh.13582 10.3324/haematol.2015.124347 10.1182/blood.V126.23.5380.5380 10.1182/blood.V126.23.27.27 10.1182/blood.V128.22.674.674 10.1182/blood-2016-01-693580 10.1056/NEJMoa1611750 10.1038/bmt.2016.214 10.1016/j.bbmt.2016.11.011 10.1111/bjh.14920 10.1002/hon.2439_151 10.1182/blood-2017-07-796607 10.1200/JCO.19.02515 10.1038/sj.bmt.1703382 10.1038/s41408-019-0205-9 10.1016/j.clml.2019.09.002 10.3109/10428194.2012.728597 10.1016/S1470-2045(20)30452-6 10.1016/S1470-2045(21)00535-0
Advances in Therapy; Yang G, Geng C et. al.

Jul 1st, 2022 - The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has become standard of care for transplant-eligible patients with newly diagnosed MM (NDMM). This study aimed to determine the efficacy of RVd as induction therapy in terms of response rates and survival outcomes of transplant-eligible patients with NDMM. The databases of Medline, Embase, and Cochrane Library were searched unt...

Combination elotuzumab and lenalidomide treatment efficacy is dependent on crosstalk be...
https://doi.org/10.3324/haematol.2021.279930
Haematologica Richardson K, Keam SP et. al.

Jul 1st, 2022 - Patients with refractory relapsed multiple myeloma (RRMM) respond to Elotuzumab (Elo) and lenalidomide (Len) combination treatment. The mechanisms underlying this observation are not fully understood. Furthermore, predictive biomarkers of response have not been revealed to date. To address these issues, we used a humanized myeloma mouse model and adoptive transfer of human NK cells to show that...

Comparison of Clinical Characteristics and Genetic Aberrations of Plasma Cell Disorders...
https://doi.org/10.1177/15330338221111228
Technology in Cancer Research & Treatment; Jirabanditsakul C, Dakeng S et. al.

Jul 1st, 2022 - Multiple myeloma is an incurable malignancy of plasma cells resulting from impaired terminal B cell development. Almost all patients with multiple myeloma eventually have a relapse. Many studies have demonstrated the importance of the various genomic mutations that characterize multiple myeloma as a complex heterogeneous disease. In recent years, next-generation sequencing has been used to iden...

Peripheral blood CD3+ T-cell gene expression biomarkers correlate with clinical frailty...
https://doi.org/10.1111/bjh.18336
British Journal of Haematology; Fell G, Rosko AE et. al.

Jun 30th, 2022 - Older patients with cancer often receive treatment regimens based on their age without considering other objective factors that may influence outcomes. Assessment of frailty can identify older patients who are robust and therefore more likely to benefit from intensive treatment, or conversely, frail and might instead be offered alternative approaches. However, such assessment requires specialis...

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consen...
https://doi.org/10.1038/s41408-022-00695-5 10.1038/s41375-021-01453-5 10.1177/20406207211027463 10.1038/s41375-021-01250-0 10.1186/s12885-021-08544-7 10.1080/14740338.2020.1733968 10.1056/NEJMoa1611750 10.3324/haematol.2015.138149 10.1016/S1470-2045(20)30756-7 10.6004/jnccn.2020.0057 10.1016/S0140-6736(19)31240-1 10.1056/NEJMoa1817249 10.1016/j.mayocp.2017.01.003 10.1002/hsr2.104 10.1111/ejh.12937 10.1056/NEJMoa1411321 10.1056/NEJMoa1516282 10.1200/JCO.21.00972 10.1056/NEJMoa1505654 10.1056/NEJMoa1607751 10.1016/S1470-2045(19)30152-4 10.1038/s41375-018-0024-1 10.1182/blood-2015-05-643320 10.1016/S0140-6736(20)30734-0 10.1016/S0140-6736(21)00592-4 10.1016/S0140-6736(19)32556-5 10.1016/S1470-2045(21)00128-5 10.1016/S1470-2045(20)30525-8 10.1016/S0140-6736(20)32292-3 10.1056/NEJMoa1714678 10.1182/bloodadvances.2020003642 10.1002/cncr.32178 10.1038/s41375-020-0711-6 10.1016/j.clml.2019.04.018 10.1016/S1470-2045(15)00464-7 10.1182/asheducation.V2014.1.255.3885263 10.1002/cncr.26422 10.1038/s41375-020-0948-0 10.1159/000486272 10.1016/j.bbmt.2015.09.016 10.1182/blood-2018-07-863829 10.1016/S2352-3026(16)30049-7 10.1016/j.bbmt.2018.12.002 10.1038/s41375-020-1005-8 10.1016/S2152-2650(21)02343-0 10.1182/blood-2015-11-682518 10.1056/NEJMoa1903455 10.1007/s40259-021-00514-6 10.1016/S1470-2045(19)30788-0 10.1056/NEJMoa1805762 10.1002/ajh.26379 10.1056/NEJMoa2024850 10.1016/S0140-6736(21)00933-8 10.1182/bloodadvances.2020004146 10.1200/JCO.21.00443 10.1182/blood-2017-06-788786 10.1002/ajh.25415 10.1016/j.clml.2020.12.021 10.1007/s00277-018-3361-2 10.1056/NEJMoa1300439 10.1200/JCO.2019.37.15_suppl.8001 10.1038/s41375-018-0271-1 10.1038/bcj.2017.13 10.3109/10428194.2011.627481 10.1038/bmt.2008.180 10.1200/JCO.2017.76.5032 10.1007/s00277-020-04384-w 10.3389/fimmu.2022.832645 10.1126/scitranslmed.abh1962 10.3109/10428194.2010.524325 10.1200/JCO.2014.59.1503 10.1038/s41375-020-01096-y 10.1182/blood-2016-02-698092 10.1038/s41591-021-01245-5 10.1038/s41467-021-21177-5 10.1158/2643-3230.BCD-20-0227 10.1182/blood-2011-06-297853 10.1182/blood-2010-10-299487 10.1093/jnci/djv225 10.1007/s11899-019-0495-9 10.1182/blood-2015-05-647636 10.1038/s41408-018-0141-0 10.1182/blood.2019000406
Blood Cancer Journal; Kumar S, Baizer L et. al.

Jun 30th, 2022 - A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the appropriate choice of treatment(s) for the next phase of the disease. Additionally, an important subset of M...

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multipl...
https://doi.org/10.1038/s41467-022-31430-0 10.1016/S0140-6736(21)00135-5 10.1038/leu.2011.368 10.1038/s41375-019-0561-2 10.1182/blood-2007-10-116129 10.1016/S1470-2045(20)30756-7 10.1016/j.clml.2015.07.178 10.1126/scitranslmed.3003161 10.1001/jama.2015.10080 10.1038/nature23306 10.1001/jamaoncol.2021.1907 10.1016/j.cell.2018.07.034 10.1038/nrc3257 10.1182/blood-2018-03-840132 10.1038/ncomms7997 10.1038/leu.2009.160 10.1016/j.ccr.2007.07.003 10.18632/oncotarget.109 10.1038/s41375-018-0108-y 10.1038/ni.1676 10.1074/jbc.M114.587808 10.1101/gad.1228704 10.1038/sj.onc.1203967 10.1016/S1074-7613(02)00398-9 10.3324/haematol.2011.054080 10.1126/science.1153629 10.1016/j.celrep.2013.12.027 10.1074/jbc.RA118.003314 10.1158/0008-5472.CAN-19-3682 10.1016/j.ccell.2015.08.001 10.1038/nature23291 10.1158/2159-8290.CD-15-0896 10.1146/annurev-genom-091212-153523 10.1038/jhg.2015.114 10.1007/s40142-016-0100-7 10.1038/ng1749 10.1038/ng2078 10.1126/science.aap8210 10.1016/S1074-7613(00)80162-4 10.1016/S1074-7613(00)80501-4 10.1038/nature07475 10.4161/onci.27090 10.1038/s41375-019-0543-4 10.1128/MCB.20.7.2423-2435.2000 10.1038/nature13527 10.1126/science.1244851 10.1158/1078-0432.CCR-18-3776 10.7326/0003-4819-105-1-8 10.1038/ng.3409 10.1186/s13045-016-0283-0 10.1016/j.bbrc.2020.12.048 10.1016/S0014-5793(99)00322-1 10.4049/jimmunol.1400499 10.4161/cc.23108 10.1146/annurev.genom.6.080604.162305 10.1038/s10038-020-00852-3 10.3324/haematol.2019.217943 10.1182/blood.2020007081 10.1038/s41392-019-0101-6 10.1101/gr.189621.115 10.1093/bioinformatics/btp352 10.1093/bioinformatics/btp394 10.1093/nar/gky1015 10.1101/gr.9.8.677 10.1093/nar/gkw971 10.1038/nature15393 10.4161/fly.19695 10.1093/nar/gks1443 10.1016/j.cell.2018.04.034 10.1093/nar/gkt996 10.1109/79.543975 10.1371/journal.pcbi.1004873 10.1186/gb-2011-12-4-r41 10.1038/ng.2702 10.1093/bioinformatics/bts635 10.1093/bioinformatics/btt656 10.1093/bioinformatics/btp616 10.1186/s13059-016-0994-0 10.1093/bioinformatics/btz588 10.1038/nature12213 10.1038/nature12912 10.1073/pnas.1616440113 10.1016/j.ajhg.2018.10.025 10.1038/nprot.2011.457 10.1371/journal.pcbi.1003665 10.1093/bioinformatics/btu314 10.1186/gb-2014-15-6-r84 10.1093/nar/gkn201 10.1111/j.1467-9868.2005.00503.x
Nature Communications; Vo JN, Wu YM et. al.

Jun 30th, 2022 - Multiple myeloma is the second most common hematological malignancy. Despite significant advances in treatment, relapse is common and carries a poor prognosis. Thus, it is critical to elucidate the genetic factors contributing to disease progression and drug resistance. Here, we carry out integrative clinical sequencing of 511 relapsed, refractory multiple myeloma (RRMM) patients to define the ...

Association of genetic variants with patient reported quality of life and pain experien...
https://doi.org/10.1038/s41409-022-01738-y 10.1111/j.1365-2141.2011.08574.x 10.1111/bjh.14514 10.1111/ijlh.12581 10.1016/j.jpainsymman.2012.11.003 10.1097/SPC.0b013e3282f04e0c 10.1016/j.pain.2013.07.044 10.1371/journal.pone.0096474 10.3390/cancers12113286 10.1007/s11011-011-9274-6 10.1038/bmt.2014.63 10.1126/science.1060952 10.1037/0735-7044.120.6.1218 10.1016/j.jpain.2004.11.008 10.1038/sj.tpj.6500327 10.1523/JNEUROSCI.22-12-05100.2002 10.2217/14622416.9.2.179 10.1016/j.pbb.2005.12.013 10.1111/j.1399-6576.2004.00517.x 10.1111/j.1399-6576.2006.01058.x 10.1002/cpdd.326 10.1038/sj.clpt.6100385 10.1016/j.jpain.2009.04.001 10.1136/annrheumdis-2012-201742 10.1016/S1470-2045(14)70245-1 10.1016/S2352-3026(16)30049-7 10.1200/JCO.18.01006 10.1158/1078-0432.CCR-06-0988 10.1093/jnci/85.5.365 10.1016/j.pain.2004.02.027 10.1111/j.2042-7158.2011.01340.x 10.2217/14622416.10.2.171 10.1146/annurev-pharmtox-061008-103222 10.1016/j.pain.2006.10.023 10.1111/bcpt.12757 10.1007/164_2016_112 10.1371/journal.pone.0075359
Bone Marrow Transplantation; Snowden JA, Ahmedzai SH et. al.

Jun 30th, 2022 - The Myeloma X trial provided a platform to explore genetics in relation to systematic assessment of patient-reported outcomes at key points during salvage treatment in multiple myeloma (MM) patients. Blood DNA was obtained in 191 subjects for single nucleotide polymorphism (SNP) genotyping. By univariable analysis, the non-coding rs2562456 SNP, upstream of LINC00664, was associated with several...

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol.
https://doi.org/10.1136/bmjopen-2022-061808
BMJ Open; Cantadori LO, Gaiolla RD et. al.

Jun 30th, 2022 - Multiple myeloma (MM) is an incurable malignant neoplasm that accounts for approximately 1% of all cancers and 10% of haematological malignancies. Bortezomib is one of the most commonly used medications in first-line treatment and subsequent relapses, either as a single agent or in combination with other therapies. This study aims to assess the effects of bortezomib on the overall survival (OS)...

Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Sys...
https://doi.org/10.1016/j.clml.2022.05.003
Clinical Lymphoma, Myeloma & Leukemia; Naser AY, Ofori-Asenso R et. al.

Jun 29th, 2022 - Oral oncolytic treatments (OOTs) have improved the prognosis of patients with multiple myeloma (MM). However, the effectiveness of these therapies is undermined by poor adherence. We aimed to characterize the real-world adherence to, and persistence with, OOTs for MM. MEDLINE, EMBASE, and the International Pharmaceutical abstracts databases were searched for relevant observational studies publi...

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of C...
https://doi.org/10.1016/j.clml.2022.04.025
Clinical Lymphoma, Myeloma & Leukemia; Weisel K, Krishnan A et. al.

Jun 29th, 2022 - This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel; CARTITUDE-1), a chimeric antigen receptor (CAR)-T-cell therapy, versus 3 non-CAR-T therapies (belantamab mafodotin [DREAMM-2], selinexor plus dexamethasone [STORM Part 2], and melphalan flufenamide plus dexamethasone [HORIZON]), each with distinct mechanisms of action, for the treatment of patients with relap...

Carfilzomib-related glomerular and tubular injury in a patient with Multiple Myeloma.
https://doi.org/10.1007/s40620-022-01367-0 10.1200/JCO.2010.30.8791 10.1093/ndt/gfp488 10.1146/annurev-pharmtox-010919-023603 10.1002/ajh.24447 10.1007/s00277-020-04062-x 10.1016/j.ekir.2016.06.002.PMID:29142917;PMCID:PMC5678606 10.1038/s41408-020-00381-4.PMID:33149167;PMCID:PMC7642386
Journal of Nephrology; Giannese D, Bonadio AG et. al.

Jun 29th, 2022 - Carfilzomib-related glomerular and tubular injury in a patient with Multiple Myeloma.|2022|Giannese D,Bonadio AG,Del Giudice ML,Cupisti A,Buda G,|

Expanding anti-CD38 immunotherapy for lymphoid malignancies.
https://doi.org/10.1186/s13046-022-02421-2 10.3322/caac.21590 10.1053/sonc.2002.33531 10.1634/theoncologist.2007-0228 10.3389/fimmu.2018.02134 10.1158/2159-8290.CD-17-1033 10.1182/blood-2017-06-740944 10.1309/74R4TB90BUWH27JX 10.3389/fimmu.2018.02722 10.1517/13543784.2014.889681 10.1016/j.clml.2018.12.013 10.1038/nrclinonc.2016.36 10.1182/blood-2011-04-348540 10.1056/NEJMoa1215134 10.1056/NEJMoa1407222 10.1056/NEJMoa2024850 10.1016/j.ymthe.2017.04.024 10.3324/haematol.2015.137620 10.1182/blood.2020004918 10.1038/leu.2015.123 10.1186/1479-5876-10-29 10.1038/s41389-020-00257-z 10.4049/jimmunol.174.5.2687 10.1016/S1074-7613(00)80353-2 10.18632/oncotarget.27508 10.3109/10428194.2011.603449 10.1016/j.leukres.2013.03.010 10.1634/theoncologist.2017-0229 10.1309/3G1XDX0DVHBNVKB4 10.1111/j.1365-2141.2007.06526.x 10.1182/blood-2017-07-794214 10.3324/haematol.2018.192757 10.1038/sj.leu.2403262 10.1007/s00277-015-2359-2 10.1056/NEJMc1605684 10.1080/2162402X.2016.1217374 10.1056/NEJM199710093371501 10.1073/pnas.0400053101 10.1182/bloodadvances.2021005220 10.1007/s12185-009-0295-4
Journal of Experimental & Clinical Cancer Research : CR; Wang X, Yu X et. al.

Jun 29th, 2022 - Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is a transmembrane glycoprotein expressed on the surface of plasma cells and MM cells. The high expression of CD38 across MM and other lymphoid malignancies and its restricted expression in normal ...

Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma
https://www.mdedge.com/fedprac/avaho/article/255829/multiple-myeloma/simultaneous-cases-carfilzomib-induced-thrombotic
Nathaniel J. Myall, MD, Samantha X. Wang, MD et. al.

Jun 28th, 2022 - As a class of drugs, proteasome inhibitors are known to rarely cause drug-induced thrombotic microangiopathy (DITMA). In particular, carfilzomib is a second-generation, irreversible proteasome inhibitor approved for the treatment of relapsed, refractory multiple myeloma (MM) in combination with other therapeutic agents.

Immunoglobulin-Related Amyloidosis
https://emedicine.medscape.com/article/208839-overview

Jun 28th, 2022 - Practice Essentials Immunoglobulin-related amyloidosis is a monoclonal plasma cell disorder in which the secreted monoclonal immunoglobulin protein forms insoluble fibrillar deposits in one or more organs. In nearly all cases, the deposits contain immunoglobulin light (L) chains or L-chain fragments, termed L chain–type amyloidosis (AL). In a few reported patients, the amyloid deposits have con...

BACTERIAL MENINGITIS IN PATIENTS WITH MULTIPLE MYELOMA: A PROSPECTIVE NATIONWIDE COHORT...
https://doi.org/10.1016/j.ijid.2022.06.038
International Journal of Infectious Diseases : IJID : Off... Sheybani F, Brouwer MC et. al.

Jun 28th, 2022 - To study the clinical features of bacterial meningitis in myeloma patients. We analyzed myeloma patients included in a nationwide cohort of patients >16 years old with community-acquired bacterial meningitis in the Netherlands between 2006 and 2018. Subsequently, we reviewed the literature for articles reporting myeloma patients with bacterial meningitis. A total of 27 of 2306 (1.6%) episodes o...

CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With...
https://doi.org/10.1016/j.clml.2022.06.001
Clinical Lymphoma, Myeloma & Leukemia; Lee D, Jain AG et. al.

Jun 28th, 2022 - CPX-351 was approved by the FDA in 2017 as frontline induction chemotherapy for patients aged ≥18 years with newly diagnosed acute myeloid leukemia (AML) which includes myelodysplasia-related changes (AML-MRC) and therapy-related acute myeloid leukemia (t-AML). The efficacy of CPX-351 among younger patients (aged <60 years) is currently unclear, as the large, randomized phase 3 study that led t...

Thromboprophylaxis in multiple myeloma.
https://doi.org/10.1080/10428194.2022.2092856
Leukemia & Lymphoma; Thalambedu N, Al Hadidi S

Jun 28th, 2022 - Venous thromboembolism (VTE) in multiple myeloma (MM) can be secondary to patient-, disease-, and/or treatment-related factors. The development of VTE may result in significant morbidity with the highest risk during the first year after diagnosis. This clinical review provides an evidence-based summary to guide practicing oncologists in the use of anticoagulation to prevent VTE in multiple myel...

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for ...
https://doi.org/10.1200/JCO.22.01040
Journal of Clinical Oncology : Official Journal of the Am... Chakraborty R, Lentzsch S

Jun 28th, 2022 - Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?|2022|Chakraborty R,Lentzsch S,|